Bridging The Gap Between Sell- And Buy- Sides In Biopharma Business Development

The biotech financing drought, combined with increasing externalization of pharma R&D, should be creating an ideal climate for successful dealmaking. Yet executing partnerships between biopharma sellers and buyers remains incredibly challenging. Locust Walk Partners surveyed senior business development executives to find the keys to executing mutually satisfying deals.

By Adam Muzikant

The challenging financing environment for biotechnology companies and increasing externalization of pharmaceutical R&D have presumably created the perfect storm for...

More from Archive

More from In Vivo

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By 

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.

Rising Leaders 2025: Abbas Kazimi’s Vision For Nimbus Therapeutics

 
• By 

Rising Leader Abbas Kazimi's leadership at Nimbus Therapeutics combines immigrant resilience, patient-first partnerships, contrarian strategic bets and a deeply personal mission driving breakthrough drug discovery innovation.

Trojan Bio Eyes Perfect Rainbow Shot With Immune System Cancer Innovations

 
• By 

Trojan Bio’s proprietary platform, based on engineered antibodies that activate the immune system to fight cancer in the same way as common viral infections, won Biomed Israel's 2025 biopharma start-up award. CEO and cofounder Anat Burkovitz said the technology is attracting investors' attention.